Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0001611535-14-000001
Filing Date
2014-06-26
Accepted
2014-06-26 18:48:13
Documents
1
Period of Report
2014-06-24

Document Format Files

Seq Description Document Type Size
1 PRIMARY DOCUMENT primary_doc.html 3  
1 PRIMARY DOCUMENT primary_doc.xml 3 2029
  Complete submission text file 0001611535-14-000001.txt   3782
Mailing Address 324 SOUTH HYDE PARK AVENUE SUITE 350 TAMPA FL 33606
Business Address 324 SOUTH HYDE PARK AVENUE SUITE 350 TAMPA FL 33606 (813) 864-2559
HedgePath Pharmaceuticals, Inc. (Issuer) CIK: 0001042418 (see all company filings)

EIN.: 541641133 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 8731 Services-Commercial Physical & Biological Research

Mailing Address LEVEL 14, 474 FLINDERS STREET MELBOURNE, VICTORIA C3 3000
Business Address LEVEL 14, 474 FLINDERS STREET MELBOURNE, VICTORIA C3 3000 011-61-3-8614-7777
Mayne Pharma Ventures Pty Ltd (Reporting) CIK: 0001611535 (see all company filings)

State of Incorp.: C3 | Fiscal Year End: 0630
Type: 3 | Act: 34 | File No.: 001-13467 | Film No.: 14943745